NCT02081014已完成2 期
A Randomized, Phase 2a, Blinded, 3-Way Crossover Dose-Ranging Study With G-Pen Mini™ (Glucagon Injection) to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Type 1 Diabetes Mellitus (T1DM)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 13
- 试验地点
- 1
- 主要终点
- Serious Adverse Events
研究概览
简要总结
The purpose of the study is to demonstrate that mini-doses of stable liquid glucagon (G-Pen Mini) produced by Xeris Pharmaceuticals are safe and effective as a treatment for mild to moderate hypoglycemia, a complication of diabetes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female subjects on insulin infusion pump therapy for treatment of type 1 diabetes
- •Between the ages of 18 and 50 years of age, inclusive, at Screening.
- •Females of childbearing potential with a negative serum pregnancy test prior at screening and negative urine pregnancy tests prior to the Treatment visits, using an approved forms of contraception for the duration of participation in the study (i.e. until after last dose).
- •Male subjects are required to use a condom and another of the methods of contraception in #3 above starting at Randomization and for the duration of the study.
- •Hemoglobin A1c (HbA1c) < 9.0 %.
- •Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study.
- •Subjects must be willing and able to comply with scheduled visits, treatment, laboratory tests and study procedures.
排除标准
- •Clinical evidence of microvascular complication(s) other than mild microalbuminuria or history of mild non-proliferative retinopathy
- •Any chronic diseases or illness that interferes with glucose metabolism, except for T1DM, or medications other than hypothyroidism on appropriate thyroid hormone replacement.
- •Blood pressure (BP) readings at Screening where Systemic BP <90 or >140 mm Hg, and Diastolic BP <50 or >90 mm Hg.
- •Cardiovascular event within 6 months prior to screening such as unstable angina, acute coronary syndrome, myocardial infarction, therapeutic coronary procedure (e.g., stent placement, Percutaneous Transluminal Coronary Angioplasty (PTCA), Coronary Artery By-pass Grafting (CABG)), stroke or transient ischemic attack.
- •Study participants who are pregnant at Screening.
- •Breast feeding must be discontinued if a subject wishes to participate in this study.
- •Positive test for hepatitis B, hepatitis C, or HIV found at Screening.
- •Positive urine drug test for illicit drugs at Screening.
- •History of allergies to glucagon, glucagon-like products or to any of the excipients in the investigational formulation.
- •Known presence of hereditary problems of glycogen storage disease, galactose and /or lactose intolerance
- •Administration of glucagon more than once within the three (3) months prior to Screening
- •Subjects with any of the following abnormalities in clinical laboratory tests at Screening, confirmed by a single repeat, if necessary:
- •Hemoglobin (Hb) below the lower limits of normal for the laboratory
- •Total bilirubin above the upper limits of normal for the laboratory
- •Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) above the upper limits of normal for the laboratory
- •Creatinine above the upper limits of normal for the laboratory
- •History of regular alcohol consumption as defined by alcohol intake in a quantity exceeding 7 drinks per week for females or 14 drinks per week for males, where 1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor.
- •Participation in other studies involving administration of an investigational drug or device within 30 days or 5 half-lives, whichever is longer, before screening for the current study and during participation in the current study
- •Whole blood donation of 1 pint (500 mL) within 8 weeks prior to Screening. Donations of plasma, packed red blood cells, platelets or quantities less than 500 mL are allowed at investigator discretion.
- •Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
研究组 & 干预措施
G-Pen Mini™ (glucagon injection) 75 ug
Experimental
G-Pen Mini™ (glucagon injection), two 75 microgram subcutaneous injections given approximately 4-5 hours apart
干预措施: G-Pen Mini™ (glucagon injection) (Drug)
G-Pen Mini™ (glucagon injection) 150 ug
Experimental
G-Pen Mini™ (glucagon injection), two 150 microgram subcutaneous injections given approximately 4-5 hours apart
干预措施: G-Pen Mini™ (glucagon injection) (Drug)
G-Pen Mini™ (glucagon injection) 300 ug
Experimental
G-Pen Mini™ (glucagon injection), two 300 microgram subcutaneous injections given approximately 4-5 hours apart
干预措施: G-Pen Mini™ (glucagon injection) (Drug)
结局指标
主要结局
Serious Adverse Events
时间窗: From first dose until follow-up call, up to 7 weeks per subject
Number of serious adverse events (SAEs) per treatment
次要结局
- Glucagon Cmax (Fasting)(Approximately 15 and 0 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, 120 and 180 minutes post-injection)
- Glucagon Cmax (Post-insulin)(Approximately 15 and 0 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, and 120 minutes post-injection)
- Glucagon Area Under the Curve (AUC) (Fasting)(Approximately 15 and 0 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, and 120 minutes post-injection)
- Glucagon AUC (Post-insulin)(Approximately 15 and 0 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, and 120 minutes post-injection)
- Glucagon Tmax (Fasting)(Approximately 15 and 0 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, 120 and 180 minutes post-injection)
- Glucagon Tmax (Post-insulin)(Approximately 15 and 0 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, and 120 minutes post-injection)
- Glucose Cmax (Fasting)(Approximately 15 and 0 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, 120 and 180 minutes post-injection)
- Glucose Cmax (Post-insulin)(Approximately 15 and 0 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, and 120 minutes post-injection)
- Glucose AUC (Fasting)(Approximately 15 and 0 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, and 120 minutes post-injection)
- Glucose AUC (Post-insulin)(Approximately 15 and 0 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, and 120 minutes post-injection)
- Glucose Tmax (Fasting)(Approximately 15 and 0 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, 120 and 180 minutes post-injection)
- Glucose Tmax (Post-insulin)(Approximately 15 and 0 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, and 120 minutes post-injection)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of G-Pen(TM) (Glucagon Injection) to Treat Severe HypoglycemiaHypoglycemiaNCT01972152Xeris Pharmaceuticals30
已完成
2 期
Equivalence of A Stable Liquid Glucagon Formulation With Freshly Reconstituted Lyophilized GlucagonType 1 DiabetesNCT02018627Steven J. Russell, MD, PhD20
已完成
1 期
Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Dasiglucagon for the Same Condition in Japanese AdolescentsDiabetes Mellitus, Type 1NCT06588504Novo Nordisk A/S38
已完成
1 期
A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Very Low Dose-Glucagon in Subjects With Type 1 Diabetes MellitusType 1 DiabetesNCT00304538DiObex10
已完成
不适用
Glucagon and Advanced HCL System to Prevent Exercise-Induced Hypoglycaemia in People With Type 1 DiabetesType 1 DiabetesHypoglycemiaNCT05379686Steno Diabetes Center Copenhagen10